Increase in covalent binding of 5-hydroxydiclofenac to hepatic tissues in rats co-treated with lipopolysaccharide and diclofenac: Involvement in the onset of diclofenac-induced idiosyncratic hepatotoxicity

Journal of Toxicological Sciences

Volumn 37, Issue 6, 2012, Pages 1143-1156

  Kishida, Tomoyuki ^a   Onozato, Tomoya ^a   Kanazawa, Toru ^a   Tanaka, Satoru ^a   Kuroda, Junji ^a  

^a KISSEI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Covalent binding; Diclofenac; GSH; Idiosyncratic hepatotoxicity; Lipopolysaccharide; Reactive metabolites

Indexed keywords

4' HYDROXYDICLOFENAC; 5 HYDROXYDICLOFENAC; CYTOCHROME P450; DANSYL GLUTATHIONE; DICLOFENAC; DRUG METABOLITE; GLUTATHIONE; LIPOPOLYSACCHARIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; COVALENT BOND; DRUG ELIMINATION; DRUG METABOLISM; HYDROXYLATION; LIVER MICROSOME; LIVER TOXICITY; MALE; NONHUMAN; RAT; TOXICOKINETICS;

EID: 84870916115     PISSN: 03881350     EISSN: 18803989     Source Type: Journal    
DOI: 10.2131/jts.37.1143     Document Type: Article

References (40)

1. Baillie, T.A. (2006): Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicology. Chem. Res. Toxicol., 19, 889-893.
2. Banks, A.T., Zimmerman, H.J., Ishak, K.G. and Harter, J.G. (1995): Diclofenac-associated hepatotoxicity: Analysis of 180 cases reported to the food and drug administration as adverse reactions. Hepaatology, 22, 820-827.
3. Beutler, B. and Rietschel, E.T. (2003): Innate immune sensing and its roots: the story of endotoxin. Nat. Rev. Immunol., 3, 169-176.
4. Boelsterli, U.A. (2003): Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol. Applied. Pharmacol., 192, 307-322.
5. Bort, R., Ponsoda, X., Jover, R., Gomez-Lechon, M.J. and Castell, J.V. (1999): Diclofenac toxicity to hepatocytes: A role for drug metabolism in cell toxicity. J. Pharmacol. Exp. Ther., 288, 65-72.
6. Buchweitz, J.P., Ganey, P.E., Bursian, S.J. and Roth, R.A. (2002): Underlying endotoxemia augments toxic responses to chlorpromazine: is there a relationship to drug idiosyncrasy? J. Pharmacol. Exp. Ther., 300, 460-467.
7. Degawa, M., Tanimura, S., Agatsuma, T. and Hashimoto, Y. (1989): Hepatocarcinogenic heterocyclic aromatic amines that induce cytochrome P-448 isozymes, mainly cytochrome P-448H (P-450ΙA2), responsible for mutagenic activation of the carcinogens in rat liver. Carcinogenesis, 10, 1119-1122.
8. Deng, X., Luyendyk, J.P., Ganey P.E. and Roth, R.A. (2009): Inflammatory stress and idiosyncratic hepatotoxicity: Hints from animal models. Pharmacol. Rev., 61, 262-282.
9. Deng, X., Stachlewitz, R.F., Liguori, M.J., Blomme, E.A.G., Waring, J.F., Luyendyk, J.P., Maddox, J.F., Ganey, P.E. and Roth, R.A. (2006): Modest inflammation enhances diclofenac hepatotoxicity in rats: role of neutrophils and bacterial translocation. J. Pharmacol. Exp. Ther., 319, 1191-1199.
10. Evans, D.C., Watt, A.P., Nicoll-Griffith, D.A. and Baillie, T.A. (2004): Drug-protein adducts: An industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol., 17, 3-16.
11. Gan, J., Harper, T.W., Hsueh, M-M., Qu, Q. and Humphreys, W.G. (2005): Dansyl glutathione as a trapping agent for the quantitative estimation and identification of reactive metabolites. Chem. Res. Toxicol., 18, 896-903.
12. Grillo, M.P., Knutson, C.G., Sanders, P.E., Waldon, D.J., Hua, F. and Ware, J.A. (2003): Studies on the chemical reactivity of diclofenac acyl glucuronide with glutathione: Identification of diclofenac-S-acyl-glutathione in rat bile. Drug Metab. Dispos., 31, 1327-1336.
13. Imaoka, S., Terano, Y. and Funae, Y. (1989): Expression of four phenobarbital-inducible cytochrome P-450s in liver, kidney, and lung of rats. J. Biochem., 105, 939-945.
14. Jaekal, J., Abraham, E., Azam, T., Netea, M.G., Dinarello, C.A., Lim, J., Yang, Y., Yoon, D. and Kim, S. (2007): Individual LPS responsiveness depends on the variation of Toll-like receptor (TLR) expression level. J. Microbiol. Biotechnol., 17, 1862-1867.
15. Kaplowitz, N. (2005): Idiosyncratic drug hepatotoxicity. Nat. Rev. Drug Discov., 4, 489-499.
16. Kim, D.H., Jung, Y.J., Lee, A.S., Lee, S., Kang, K.P., Lee, T.H., Lee, S.Y., Jang, K.Y., Moon, W.S., Choi, K., Yoon, K., Sung, M.J., Park, S.K. and Kim, W. (2009): COMP-Angiopoietin-1 decreases lipopolysaccharide-induced acute kidney injury. Kidney Int., 76, 1180-1191.
17. Kishida, T., Muto, S., Hayashi, M., Tsutsui, M., Tanaka, S., Murakami, M. and Kuroda, J. (2008): Strain differences in hepatic cytochrome P450 1A and 3A expression between Sprague-Dawley and Wistar rats. J. Toxicol. Sci., 33, 447-457.
18. Lewis, J.H. (2003): Nonsteroidal anti-inflammatory drugs: Pathology and clinical presentation of hepatotoxicity. In Drug-Induced Liver Disease (Kaplowitz, N., Deleve, L.D. ed.), pp.377-404, Marcel Dekker, New York.
19. Lowry, O.H., Rosebrough, N.J., Farr, A.L. and Randall, R.J. (1951): Protein measurement with the folin phenol reagent. J. Biol. Chem., 193, 265-275.
20. Luyendyk, J.P., Lehman-McKeeman, L.D., Nelson, D.M., Bhaskaran, V.M., Reilly, T.P., Car, B.D., Cantor, G.H., Deng, X., Maddox, J.F., Ganey, P.E. and Roth, R.A. (2006): Coagulation-dependent gene expression and liver injury in rats given lipopolysaccharide with ranitidine but not with famotidine. J. Pharmacol. Exp. Ther., 317, 635-643.
21. Masubuchi, Y., Ose, A. and Horie, T. (2001): Mechanism-based inactivation of CYP2C11 by diclofenac. Drug Metab. Dispos., 29, 1190-1195.
22. Masubuchi, Y., Ose, A. and Horie, T. (2002): Diclofenac-induced inactivation of CYP3A4 and its stimulation by quinidine. Drug Metab. Dispos., 30, 1143-1148.
23. Mohamadin, A.M., Elberry, A.A., Elkablawy, M.A., Abdel Gawad, H.S. and Al-Abbasi, F.A. (2011): Montelukast, a leukotriene receptor antagonist abrogates lipopolysaccharide-induced toxicity and oxidative stress in rat liver. Pathophysiology, 18, 235-242.
24. Morgan, E.T. (2009): Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin. Pharmacol. Ther., 85, 434-438.
25. Naisbitt, D.J., Sanderson, L.S., Meng, X., Stachulski, A.V., Clarke, S.E. and Park, B.K. (2007): Investigation of the immunogenicity of diclofenac and diclofenac metabolites. Toxicol. Lett., 168, 45-50.
26. Omura, T. and Sato, R. (1964): The carbon monoxide-binding pigment of liver microsomes. J. Biol. Chem., 239, 2370-2378.
27. Park, B.K., Kitteringham, N.R., Powell, H. and Pirmohamed, M. (2000): Advances in molecular toxicology-towards understanding idiosyncratic drug toxicity. Toxicology, 153, 39-60.
28. Pirmohamed, M., Naisbitt, D.J., Gordon, F. and Park, B.K. (2002): The danger hypothesis-potential role in idiosyncratic drug reactions. Toxiology, 181-182, 55-63.
29. Roth, R.A., Luyendyk, J.P., Maddox, J.F. and Ganey, P.E. (2003): Inflammation and drug idiosyncrasy-is there a connection? J. Pharmacol. Exp. Ther., 307, 1-8.
30. Shaw, P.J., Ganey, P.E. and Roth, R.A. (2010): Idiosyncratic druginduced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity. Toxicol. Sci., 118, 7-18.
31. Shen, S., Marchick, M.R., Davis, M.R., Doss, G.A. and Pohl, L.R. (1999): Metabolic activation of diclofenac by human cytochrome P450 3A4: Role of 5-hydroxydiclofenac. Chem. Res. Toxicol., 12, 214-222.
32. Sompamit, K., Kukongviriyapan, U., Nakmareong, S. and Kukongviriyapan, V. (2009): Curcumin improves vascular function and alleviates oxidative stress in non-lethal lipopolysaccharide-induced endotoxaemia in mice. Eur. J. Pharmacol., 616, 192-199.
33. Tanaka, S., Tsutsui, M., Kishida, T., Souma, S., Kuroda, J., Yoshida, T. (2010): Salbutamol inhibits lipopolysaccharide-induced inflammatory responses in rat peritoneal macrophages. J. Toxicol. Sci., 35, 327-334.
34. Uetrecht, J. (2008): Idiosyncratic drug reactions: Past, present, and future. Chem. Res. Toxicol., 21, 84-92.
35. Walgren, J.L., Mitchell, M.D. and Thompson, D.C. (2005): Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit. Rev. Toxicol., 35, 325-361.
36. Walker, A.M. (1997): Quantitative studies of the risk of serious hepatic injury in persons using nonsteroidal antiinflammatory drugs. Arthritis Rheum., 40, 201-208.
37. Waring, J.F. and Anderson, M.G. (2005): Idiosyncratic toxicity: mechanistic insights gained from analysis of prior compounds. Curr. Opin. Drug Discov. Dev., 8, 59-65.
38. Waring, J.F., Liguori, M.J., Luyendyk, J.P., Maddox, J.F., Ganey, P.E., Stachlewitz, R.F., North, C., Blomme E.A.G. and Roth, R.A. (2006): Microarray analysis of lipopolysaccharide potentiation of trovafloxacin-induced liver injury in rats suggests a role for proinflammatory chemokines and neutrophils. J. Pharmacol. Exp. Ther., 316, 1080-1087.
39. Yano, K., Sekine, S., Nemoto, K., Fuwa, T. and Horie, T. (2010): The effect of dimerumic acid on LPS-induced downregulation of Mrp2 in the rat. Biochem. Pharm., 80, 533-539.
40. Zou, W., Roth, R.A., Younis, H.S., Burgoon, H.S. and Ganey, P.E. (2010): Oxidative stress is important in the pathogenesis of liver injury induced by sulindac and lipopolysaccharide cotreatment. Toxicology, 272, 32-38.